IQVIA Holdings Inc. (IQV)
| Market Cap | 42.70B +31.4% |
| Revenue (ttm) | 16.98B +8.2% |
| Net Income | 1.38B +11.2% |
| EPS | 8.08 +16.7% |
| Shares Out | 164.60M |
| PE Ratio | 32.12 |
| Forward PE | 19.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 901,366 |
| Open | 258.59 |
| Previous Close | 260.24 |
| Day's Range | 256.45 - 261.80 |
| 52-Week Range | 154.50 - 261.88 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 275.17 (+6.07%) |
| Earnings Date | Jul 28, 2026 |
About IQV
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers ... [Read more]
Financial Performance
In 2025, IQVIA Holdings's revenue was $16.31 billion, an increase of 5.87% compared to the previous year's $15.41 billion. Earnings were $1.36 billion, a decrease of -0.95%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for IQV stock is "Strong Buy." The 12-month stock price target is $275.17, which is an increase of 6.07% from the latest price.
News
IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
Iqvia, Medera partner to advance cardiac gene therapy
Iqvia (IQV) and Medera announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms. The collaboration brings together IQVIA’s g...
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
RESEARCH TRIANGLE PARK, N.C. & BOSTON--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences ...
Iqvia price target raised to $247 from $221 at RBC Capital
RBC Capital raised the firm’s price target on Iqvia (IQV) to $247 from $221 and keeps an Outperform rating on the shares after its Q2 earnings beat. The inflection in…
Iqvia price target raised to $288 from $233 at TD Cowen
TD Cowen raised the firm’s price target on Iqvia (IQV) to $288 from $233 and keeps a Buy rating on the shares. The firm said the company attributed strong bookings…
Iqvia price target raised to $280 from $245 at BofA
BofA raised the firm’s price target on Iqvia (IQV) to $280 from $245 and keeps a Buy rating on the shares. Q2 results were ahead of expectations, further strengthening the…
Iqvia price target raised to $270 from $210 at BMO Capital
BMO Capital analyst Sean Dodge raised the firm’s price target on Iqvia (IQV) to $270 from $210 and keeps an Outperform rating on the shares. The company’s Q2 results were…
Iqvia price target raised to $285 from $225 at JPMorgan
JPMorgan raised the firm’s price target on Iqvia (IQV) to $285 from $225 and keeps an Overweight rating on the shares.
Iqvia price target raised to $276 from $220 at Stifel
Stifel analyst Shlomo Rosenbaum raised the firm’s price target on Iqvia (IQV) to $276 from $220 and keeps a Buy rating on the shares.
Iqvia price target raised to $287 from $252 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Iqvia (IQV) to $287 from $252 and keeps an Outperform rating on the shares.
Iqvia price target raised to $240 from $200 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Iqvia (IQV) to $240 from $200 and keeps an Equal Weight rating on the shares following the Q2 report. The firm says…
Iqvia price target raised to $275 from $210 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Iqvia (IQV) to $275 from $210 and keeps an Overweight rating on the shares. The firm updated the company’s model…
This Healthcare Stock Is Today's Best in the S&P 500
IQVIA Holdings leads the index after the company boosted its full-year outlook on the back of a strong second quarter.
IQVIA raises annual profit forecast on clinical research demand
IQVIA Holdings raised its annual profit forecast on Tuesday after reporting better-than-expected second-quarter results, driven by strong demand for its healthcare data and analytics services, sendi...
IQVIA Holdings Earnings Call Transcript: Q2 2026
Second quarter results exceeded guidance, with revenue up 8.7% and adjusted EPS up 12.1% year-over-year. Both clinical and commercial segments showed strong growth, driven by AI-enabled solutions and robust demand. Full-year guidance was raised across all key metrics.
IQVIA Holdings Earnings release: Q2 2026
IQVIA Holdings released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
IQVIA Holdings Slides: Q2 2026
IQVIA Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
IQVIA Holdings Quarterly report: Q2 2026
IQVIA Holdings has published its Q2 2026 quarterly earnings report on July 28, 2026.
Iqvia reports Q2 EPS $3.15, consensus $3.03
Reports Q2 revenue $4.368B, consensus $4.3B. “In a strengthening market environment, the IQVIA (IQV) team executed well and delivered outstanding results, exceeding the high-end of our expectations fo...
IQVIA Reports Second-Quarter 2026 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
Iqvia price target raised to $230 from $215 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on Iqvia (IQV) to $230 from $215 and keeps an Outperform rating on the shares. The firm adjusted targets in the…
Iqvia named short-term buy idea at Deutsche Bank
Deutsche Bank placed a “Catalyst call: Buy” on shares of Iqvia (IQV) as a short-term investment idea. Iqvia has traded down 10% year-to-date and has underperformed peers despite 2026 guidance…
IQVIA to Announce Second-Quarter 2026 Results on July 28, 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...